Summary
TP PHARMA has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1,500. Its solvency ranks better than 24% of 9,557 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Financials · financial year 2025, micro format
Source amounts without an identifiable currency are assumed to be EUR.
Turnover and EBIT margin not published: the micro format does not require them.
| Line | 2025 |
|---|---|
| Other operating charges640/8 | €341 |
| Gross operating margin9900 | €346 |
| Operating profit (loss)9901 | €5 |
| Financial charges65/66B | €5 |
| Recurring financial charges65 | €5 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €8,704 | |
| Current assets29/58 | €8,704 | |
| Amounts receivable within one year40/41 | €8,347 | |
| Trade receivables40 | €7,725 | |
| Other amounts receivable41 | €622 | |
| Cash at bank and in hand54/58 | €357 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €8,704 | |
| Equity10/15 | €1,500 | |
| Contributions10/11 | €1,500 | |
| Amounts payable17/49 | €7,204 | |
| Amounts payable within one year42/48 | €7,204 | |
| Trade debts44 | €2,505 | |
| Suppliers440/4 | €2,505 | |
| Other amounts payable47/48 | €4,700 | |
Not filed in this scheme.
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 10-02-2026 | 2026-00036858 |
Similar companies · same sector, comparable size
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.